rct
2012
High Quality
Aspirin for Preventing the Recurrence of Venous Thromboembolism (WARFASA)
Becattini C, Agnelli G, Schenone A
Published in New England Journal of Medicine
Methodology
Multicentre, double-blind, placebo-controlled trial of aspirin 100 mg daily after 6-18 months of anticoagulation for unprovoked venous thromboembolism.
Key Findings
Recurrent venous thromboembolism occurred in 6.6% per year with aspirin versus 11.2% with placebo, without increased bleeding.
Conclusions
Aspirin reduces recurrence risk after anticoagulation is stopped, though less effectively than anticoagulants.
Limitations
Not a comparison against continued anticoagulation.
Related Health Concerns
Study Details
Year:2012
Sample Size:402
Duration:104 weeks
Quality Score:9/10
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.